Hyaluron pen filler template

Key Takeaways

In October 2021, the FDA issued a safety communication advising against using hyaluron pens to inject dermal filler at all, because the device cannot control injection depth or placement.

Documented complications include vascular occlusion, infection, necrosis, nodules, asymmetry, and vision loss – all must be disclosed in consent forms.

Hyaluron pen treatments are offered by both licensed and unlicensed practitioners, and practices can face liability exposure managing complications regardless of who performed the original treatment.

Practice management software like Pabau can help practices operationalize compliant documentation and aftercare messaging, whether they manage hyaluron pen complications or offer safer needle-based alternatives.

Download your free hyaluron pen filler template

Some patients have undergone hyaluron pen filler treatment; others just ask about it. Either way, your practice needs a consent and screening template to protect your patients and your practice.

The hyaluron pen is a needle-free device that uses high-pressure air to deliver hyaluronic acid filler. Still, the FDA advises against using it for filler injection at all. The device cannot control injection depth or placement.

This guide covers the documentation your practice needs. That applies whether you are managing complications from treatment performed elsewhere or evaluating safer, needle-based alternatives.

What is a hyaluron pen filler?

A hyaluron pen filler is a device that delivers hyaluronic acid-a naturally occurring skin moisturizer-into the dermis using high-pressure air instead of a traditional needle. The device injects filler material without a visible entry point. This appeals to patients who are needle-phobic or attracted to the “needle-free” marketing claim. Treatment areas typically include lips, nasolabial folds, under-eye zones, and cheeks.

In October 2021, the FDA issued a safety communication. It warned the public and healthcare professionals not to use needle-free devices such as hyaluron pens to inject dermal filler. That warning applies regardless of who operates the device.

The FDA’s concern is the device itself. It forces filler into tissue using high pressure and cannot control injection depth or placement. This raises the risk of vascular occlusion, blindness, allergic reaction, infection, and disease transmission. No hyaluron pen device is FDA-approved for filler injection.

Despite the warning, the devices are still sold online and marketed as a safer, needle-free alternative to traditional filler injections.

How to use the hyaluron pen filler template

The hyaluron pen filler template is a consent and screening form. It supports your practice’s documentation workflow across three steps:

1. Pre-treatment screening: Document patient medical history, current medications, previous filler experience, and absolute contraindications (active skin infection, pregnancy, certain medications). The form flags relative contraindications (isotretinoin within 6 months, recent surgery) for practitioner review.
2. Risk disclosure, FDA disclosure, and consent: Present the full risk list-vascular occlusion, infection, necrosis, nodules, asymmetry, blindness-in plain language, with specific warnings for high-risk zones such as the periocular area. Add explicit disclosure that the device is not FDA-approved and that the FDA advises against its use. Then obtain a dated patient signature.
3. Treatment records and aftercare, kept separately: This form covers consent and screening only. Log treatment details (product, lot number, volume, injection sites, practitioner) and aftercare instructions in your practice’s own clinical record system. Keep them out of this template.

The consent form integrates into your practice’s digital workflow via digital consent forms, while you can handle treatment records and aftercare messaging separately through digital treatment records, keeping everything timestamped, encrypted, and audit-ready. This approach reduces the liability exposure that paper-based documentation creates.

Who is the hyaluron pen filler template helpful for?

This template is useful for practices that manage hyaluron pen filler complications. It also helps those weighing whether to offer the treatment despite the FDA’s warning against it. Specifically:

• Aesthetic and med spa practices that see patients presenting with hyaluron pen complications and need compliant documentation for liability protection.
• Dermatology practices evaluating hyaluron pen filler complications (nodules, vascular events, infections) and needing structured referral and reversal protocols.
• Plastic surgery and cosmetic surgery centers offering corrective procedures for hyaluron pen outcomes. They also require treatment records for surgical consultation and post-operative follow-up.
• Practices that choose to proceed with hyaluron pen treatment despite the FDA’s warning. They must document that they informed the patient of the FDA’s advice against use and the device’s risks.
• Practices evaluating needle-based filler injection as a safer alternative and needing consent frameworks compliant with state scope-of-practice regulations.
• Spa and wellness practices that do not offer hyaluron pen treatment. They need to recognize complications and triage patients to medical practitioners.

Benefits of using the hyaluron pen filler template

A structured hyaluron pen filler template protects your practice and your patients in five ways:

Regulatory compliance: This form does not, by default, disclose the FDA’s non-approval status. It also omits the 2021 safety communication advising against hyaluron pen use. Add that disclosure yourself before using the form with patients.

Documented disclosure matters for medical board inquiries and, for UK practices, CQC inspections. If a patient develops a complication and claims they were not informed of the risks. A signed consent form that includes this disclosure is your first line of defense.

Risk disclosure and informed consent: The template names specific documented complications (vascular occlusion with risk of vision loss, necrosis, infection). It avoids generic “side effects” language. Courts and regulators view specific risk disclosure as evidence of informed consent. Broad disclaimers without named risks do not meet the standard of care.

Clinical audit trail: Keep treatment records that log patient ID, product lot numbers, volumes, and anatomical sites. Keep them separate from this consent form. If a complication develops and a patient claims they received a different treatment or dose, those records establish what the practitioner actually delivered. This is critical for defending against malpractice claims and regulatory investigations.

Complication escalation and patient safety: Written aftercare instructions, kept separately from this consent form, that define warning signs (vision changes, severe pain, skin blanching) and escalation pathways (immediate practice call vs. emergency department) help patients know when to seek urgent care. This reduces the risk of delays in managing vascular occlusion or infection.

GDPR and HIPAA compliance: When implemented via medical spa management software, the platform encrypts consent forms and records, controls access to them, and retains them automatically according to your jurisdiction’s data protection requirements (GDPR in the UK, HIPAA in the US). Manual paper records lack this audit control.

Managing patients presenting with hyaluron pen complications

Your practice may see patients who had hyaluron pen treatment elsewhere and now present with complications. Document your assessment and management protocols in your treatment record.

Initial assessment: Document the timeline of treatment (date and location), filler product claimed (hyaluronic acid vs. other materials), volume injected, and zones treated.

Ask when symptoms began: immediate swelling and asymmetry suggest operator over-fill or off-target injection; delayed nodules (weeks to months) suggest a granulomatous response or biofilm formation; blanching and severe pain (hours after treatment) indicate vascular compromise, a medical emergency.

Vascular occlusion and vision loss: If a patient reports vision changes, orbital pain, or skin blanching in the periocular or nasolabial zones within 24-48 hours of treatment, this is vascular occlusion until proven otherwise. Call emergency medicine or ophthalmology immediately.

Hyaluronidase reversal (typically 300-600 IU) may apply, but only a physician or advanced practice provider with ophthalmology backup should administer it. Document your referral pathway and escalation decision point in your practice’s own protocol.

Infection and necrosis: Signs of infection (fever, purulent drainage, spreading erythema, warmth) warrant culture, antibiotic therapy, and specialist referral (dermatology or infectious disease). Necrosis (eschar, blackened or gangrenous-appearing tissue) requires urgent surgical consultation and possible debridement. Document all signs, treatments offered, and whether the patient accepted or declined referral.

Nodules and asymmetry: If sterile nodules or palpable lumps develop weeks after treatment, consider whether the patient will accept observation, steroid injection, or massage. If the patient requests reversal, you can inject hyaluronidase (150-300 IU per nodule) directly. A discharge planning checklist can help you capture the patient’s preference and the rationale for your chosen management approach.

Use your practice’s compliance management tools to log all complication cases. Over time, this data reveals patterns (certain practitioners, certain products, certain anatomical zones) that warrant protocol adjustments or practitioner retraining.

Safe alternatives to hyaluron pen filler for practices

If your practice offers filler services, needle-based hyaluronic acid injection by a licensed practitioner (physician, nurse practitioner, or physician assistant, depending on your jurisdiction) is the only approach consistent with the FDA’s 2021 safety communication advising against hyaluron pens. Here’s why:

• Regulatory approval: FDA-approved dermal fillers (Restylane, Juvéderm, Radiesse, Sculptra) come with prescribing information, adverse event surveillance, and post-market safety monitoring. Hyaluron pens have none of this.
• Operator training: Licensed practitioners complete anatomy training, injection technique certification, and complication management protocols. Hyaluron pen suppliers often provide minimal training.
• Precision control: A needle allows precise depth control (intradermal vs. subcutaneous vs. deep), flow rate adjustment, and real-time tactile feedback. Pressurized air delivery is less controllable, especially near vascular and neural structures.
• Complication management: If hyaluronic acid enters a blood vessel, a licensed practitioner trained in hyaluronidase reversal can act immediately. Hyaluron pen users outside a licensed practice setting lack this skill.

When you operationalize needle-based filler treatment within your practice using digital consent forms and treatment records via aesthetic EMR software, you create an auditable, compliant clinical workflow. AI-powered clinical documentation can auto-populate sections of your treatment note (patient history, consent checkboxes, aftercare steps). This reduces the time burden on your clinicians while ensuring nothing is omitted.

Pabau’s skin clinic management platform integrates digital consent forms, anatomical injection plotting (showing exactly where you placed the filler), and automated aftercare messaging. This combination reduces liability exposure and improves patient safety monitoring compared to paper-based workflows or standalone consent tools.

See How Pabau Protects Your Practice

Digital consent forms, treatment records, and aftercare automation built for aesthetic practitioners. GDPR and HIPAA compliant.

Book a demo

Conclusion

The hyaluron pen carries risk regardless of who operates it: the needle-free pitch and lower cost draw patients in, but the FDA advises against the device for filler injection, and complications can range from minor asymmetry to vision loss.

Your hyaluron pen filler consent and screening template supports the documentation your practice needs. That applies whether you are managing complications from treatment performed elsewhere or evaluating whether to offer needle-based filler instead. Download the template above. Customize it for your jurisdiction (UK practices should note CQC oversight; US practices should confirm state scope-of-practice rules).

Add it to your digital workflow via HIPAA-compliant practice software or structured clinical documentation platforms.

Expert picks

Continue your research

Need a framework for documenting complex clinical decisions? Medical Decision Making explains how documented reasoning strengthens your clinical record when a case does not fit a standard protocol.

Looking for a consent form for other aesthetic procedures? Dermal Filler Consent Form covers broad-spectrum filler treatments and can be adapted for your practice’s scope.

Need a screening form for other treatments? Family Medical History Form covers the intake questions that support contraindication screening across aesthetic procedures.

Frequently asked questions